BACKGROUND: Campylobacter jejuni is the predominant cause of antecedent infection in post-infectious neuropathies such as the Guillain-Barré (GBS) and Miller Fisher syndromes (MFS). GBS and MFS are probably induced by molecular mimicry between human gangliosides and bacterial lipo-oligosaccharides (LOS). This study describes a new C. jejuni-specific high-throughput AFLP (htAFLP) approach for detection and identification of DNA polymorphism, in general, and of putative GBS/MFS-markers, in particular. RESULTS: We compared 6 different isolates of the "genome strain" NCTC 11168 obtained from different laboratories. HtAFLP analysis generated approximately 3000 markers per stain, 19 of which were polymorphic. The DNA polymorphisms could not be confirmed by PCR-RFLP analysis, suggesting a baseline level of 0.6% AFLP artefacts. Comparison of NCTC 11168 with 4 GBS-associated strains revealed 23 potentially GBS-specific markers, 17 of which were identified by DNA sequencing. A collection of 27 GBS/MFS-associated and 17 enteritis control strains was analyzed with PCR-RFLP tests based on 11 of these markers. We identified 3 markers, located in the LOS biosynthesis genes cj1136, cj1138 and cj1139c, that were significantly associated with GBS (P = 0.024, P = 0.047 and P < 0.001, respectively). HtAFLP analysis of 13 highly clonal South African GBS/MFS-associated and enteritis control strains did not reveal GBS-specific markers. CONCLUSION: This study shows that bacterial GBS markers are limited in number and located in the LOS biosynthesis genes, which corroborates the current consensus that LOS mimicry may be the prime etiologic determinant of GBS. Furthermore, our results demonstrate that htAFLP, with its high reproducibility and resolution, is an effective technique for the detection and subsequent identification of putative bacterial disease markers.
BACKGROUND:Campylobacter jejuni is the predominant cause of antecedent infection in post-infectious neuropathies such as the Guillain-Barré (GBS) and Miller Fisher syndromes (MFS). GBS and MFS are probably induced by molecular mimicry between humangangliosides and bacterial lipo-oligosaccharides (LOS). This study describes a new C. jejuni-specific high-throughput AFLP (htAFLP) approach for detection and identification of DNA polymorphism, in general, and of putative GBS/MFS-markers, in particular. RESULTS: We compared 6 different isolates of the "genome strain" NCTC 11168 obtained from different laboratories. HtAFLP analysis generated approximately 3000 markers per stain, 19 of which were polymorphic. The DNA polymorphisms could not be confirmed by PCR-RFLP analysis, suggesting a baseline level of 0.6% AFLP artefacts. Comparison of NCTC 11168 with 4 GBS-associated strains revealed 23 potentially GBS-specific markers, 17 of which were identified by DNA sequencing. A collection of 27 GBS/MFS-associated and 17 enteritis control strains was analyzed with PCR-RFLP tests based on 11 of these markers. We identified 3 markers, located in the LOS biosynthesis genes cj1136, cj1138 and cj1139c, that were significantly associated with GBS (P = 0.024, P = 0.047 and P < 0.001, respectively). HtAFLP analysis of 13 highly clonal South African GBS/MFS-associated and enteritis control strains did not reveal GBS-specific markers. CONCLUSION: This study shows that bacterial GBS markers are limited in number and located in the LOS biosynthesis genes, which corroborates the current consensus that LOS mimicry may be the prime etiologic determinant of GBS. Furthermore, our results demonstrate that htAFLP, with its high reproducibility and resolution, is an effective technique for the detection and subsequent identification of putative bacterial disease markers.
Authors: H P Endtz; C W Ang; N van Den Braak; B Duim; A Rigter; L J Price; D L Woodward; F G Rodgers; W M Johnson; J A Wagenaar; B C Jacobs; H A Verbrugh; A van Belkum Journal: J Clin Microbiol Date: 2000-06 Impact factor: 5.948
Authors: P Vos; R Hogers; M Bleeker; M Reijans; T van de Lee; M Hornes; A Frijters; J Pot; J Peleman; M Kuiper Journal: Nucleic Acids Res Date: 1995-11-11 Impact factor: 16.971
Authors: J Parkhill; B W Wren; K Mungall; J M Ketley; C Churcher; D Basham; T Chillingworth; R M Davies; T Feltwell; S Holroyd; K Jagels; A V Karlyshev; S Moule; M J Pallen; C W Penn; M A Quail; M A Rajandream; K M Rutherford; A H van Vliet; S Whitehead; B G Barrell Journal: Nature Date: 2000-02-10 Impact factor: 49.962
Authors: J Engberg; I Nachamkin; V Fussing; G M McKhann; J W Griffin; J C Piffaretti; E M Nielsen; P Gerner-Smidt Journal: J Infect Dis Date: 2001-06-08 Impact factor: 5.226
Authors: B Duim; C W Ang; A van Belkum; A Rigter; N W van Leeuwen; H P Endtz; J A Wagenaar Journal: Appl Environ Microbiol Date: 2000-09 Impact factor: 4.792
Authors: Michel Gilbert; Peggy C R Godschalk; Marie-France Karwaski; C Wim Ang; Alex van Belkum; Jianjun Li; Warren W Wakarchuk; Hubert P Endtz Journal: Infect Immun Date: 2004-02 Impact factor: 3.441
Authors: C Wim Ang; Jeroen R Dijkstra; Marcel A de Klerk; Hubert Ph Endtz; Pieter A van Doorn; Bart C Jacobs; Suzan H M Jeurissen; Jaap A Wagenaar Journal: PLoS One Date: 2010-03-22 Impact factor: 3.240
Authors: Eduardo N Taboada; Alex van Belkum; Nobuhiro Yuki; Rey R Acedillo; Peggy Cr Godschalk; Michiaki Koga; Hubert P Endtz; Michel Gilbert; John He Nash Journal: BMC Genomics Date: 2007-10-05 Impact factor: 3.969
Authors: Beatriz Quiñones; Magalie R Guilhabert; William G Miller; Robert E Mandrell; Albert J Lastovica; Craig T Parker Journal: PLoS One Date: 2008-04-23 Impact factor: 3.240
Authors: Guillaume Méric; Alan McNally; Alberto Pessia; Evangelos Mourkas; Ben Pascoe; Leonardos Mageiros; Minna Vehkala; Jukka Corander; Samuel K Sheppard Journal: Genome Biol Evol Date: 2018-03-01 Impact factor: 3.416